Research To Practice

•

Canal • 10 podcasts

Ciência

Ciência

Semanal
Ciência

Ciência

Semanal
Ciência

Ciência

Semanal
Ciência

Ciência

Mensal
Ciência

Ciência

Semanal
Ciência

Ciência

Semanal
Ciência

Ciência

Bimestral

14/10/2025 · VÍDEO

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

Featuring an interview with Dr Laura Huppert, including the following topics: General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00) Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44) Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30) Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13) Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25) CNS penetration and activity of ADCs in the treatment of breast cancer (22:27) Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24) Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05) Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51) Ongoing evaluation of ADCs in the localized disease setting (35:42) Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38) CME information and select publications

14/10/2025 · Vídeo

•

44min
13/12/2025 · VÍDEO

Gastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology Network

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics: Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00) Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24) Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34) Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15) Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23) Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54) CE information and select publications

13/12/2025 · Vídeo

•

50min
HÁ 3 DIAS

Metastatic Bladder Cancer — Rapid Case Review Issue 2

Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York. CME information and select publications here.

há 3 dias

•

29min
2 DE FEV.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.

2 de fev.

•

1h57min
13/10/2025 · VÍDEO

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics: Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00) Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18) Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10) CME information and select publications

13/10/2025 · Vídeo

•

31min
21/10/2025 · VÍDEO

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics: Introduction: Antibody-drug conjugates in localized breast cancer (0:00) Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46) Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07) Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49) Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan after experiencing disease progression on capecitabine — Laila Agrawal, MD (38:37) Case: A woman in her late 50s with ER-negative, HER2-low mBC receives trastuzumab deruxtecan after experiencing disease progression on sacituzumab govitecan — Kimberly Ku, MD (44:24) Case: A woman in her early 60s with ER-positive, HER2-low mBC and hyperglycemia receives trastuzumab deruxtecan after experiencing disease progression on capivasertib/fulvestrant — Eleonora Teplinsky, MD (48:50) CME information and select publications

21/10/2025 · Vídeo

•

57min
3 DE JAN. · VÍDEO

Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

Featuring perspectives from Dr Harry Paul Erba, Dr Amir Fathi, Dr Tara L Lin, Dr Alexander Perl and Dr Eytan M Stein, including the following topics: Introduction (0:00) Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin (1:46) Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl (25:38) Role of FLT3 Inhibitors in AML Management — Dr Erba (48:27) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi (1:10:28) Current and Future Role of Menin Inhibitors in the Treatment of AML — Dr Stein (1:37:29) CME information and select publications

3 de jan. · Vídeo

•

1h58min
07/10/2025 · VÍDEO

Breast Cancer — An ASCO 2025 Review

Featuring perspectives from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics: Introduction: View from Outer Space (0:00) Hormone Receptor-Positive Breast Cancer (6:23) HER2-Positive Breast Cancer (40:54) Triple-Negative Breast Cancer (52:48) CME information and select publications

07/10/2025 · Vídeo

•

1h2min
11 DE FEV.

Squamous Cell Carcinoma of the A**l Canal — An Interview with Dr Marwan Fakih

Dr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the a**l canal. CME information and select publications here.

11 de fev.

•

37min
4 DE FEV.

Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress. CME information and select publications here.

4 de fev.

•

31min

CME education for oncology clinicians. Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

Site